Accueil   Diary - News   All news iDD biotech in collaboration with Genmab

iDD biotech in collaboration with Genmab

Milestone achievement in DR5 antibody collaboration

 

 

iDD biotech announces the achievement of the first milestone under the agreement signed one year ago with Genmab A/S, a publicly traded, international biotechnology company specializing in the creation and development of differentiated human antibody therapeutics for the treatment of cancer.


Genmab has selected iDD biotech’s antibody as a clinical candidate for further development. Under the terms of the agreement, Genmab will pay iDD Biotech a fee of EUR 3.5 million.

 

 

Read the press release

 

 

By continuing your navigation on our site, you accept the use of cookies and the collection of your data and personal information by Lyonbiopôle, for the purposes of measuring the traffic on the website, to provide statistics and to offer you adapted content to your centers of interest. To exercise your rights of access, rectification, opposition, deletion and portability, in accordance with the General Data Protection Regulation (EU 2016/679), you are informed that you can send your request to dpo@lyonbiopole.com. More details are available by clicking here I agree